Lamivudine and Therapeutic Vaccine Evaluation in Senegalese Patients With Chronic Hepatitis B Infection (ANRS 12100 HEPADAK-2)

NCT00120796 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

8

Enrollment

OTHER_GOV

Sponsor class

Stopped poor patient recrutment

Conditions

Hepatitis B

Interventions

DRUG: Lamivudine
BIOLOGICAL: Recombinant hepatitis B surface antigen

Sponsor

French National Agency for Research on AIDS and Viral Hepatitis

Collaborators

[object Object]